The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH
Wang T. -., Zwicker J. I., d m. n. A. D., Pabinger I., Falanga A., Antic D., Noble S., Khorana A. A., Carrier M., Meyer G.
Journal of Thrombosis and Haemostasis
Vol.17, Issue10, P. 1772-1778
Опубликовано: 2019
Тип ресурса: Статья
Аннотация:
[краткое описание не найдено]
Ключевые слова:
anticoagulant agent; apixaban; low molecular weight heparin; rivaroxaban; apixaban; blood clotting factor 10a inhibitor; pyrazole derivative; pyridone derivative; rivaroxaban; ambulatory care; anticoagulant therapy; Article; cancer chemotherapy; cancer patient; cancer regression; clinical outcome; disease burden; drug dose regimen; drug efficacy; drug use; evidence based medicine; human; morbidity; mortality; patient preference; patient selection; practice guideline; primary prevention; priority journal; randomized controlled trial (topic); thrombosis prevention; treatment duration; treatment response; venous thromboembolism; blood; complication; neoplasm; oral drug administration; risk factor; treatment outcome; venous thromboembolism; Administration, Oral; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism
Язык текста: Английский
ISSN: 1538-7836
Wang T. -. T.-F.
Zwicker J. I.
m. n. A. D. m n Ay Dzhikhan 1980-
Pabinger I.
Falanga A.
Antic D.
Noble S.
Khorana A. A.
Carrier M.
Meyer G.
Wанг Т. -. Т.-Ф.
Зwиcкер Й. И.
м. н. А. Д. м н Ай Джихан 1980-
Пабингер И.
Фаланга А.
Антиc Д.
Нобле С.
Хорана А. А.
Cарриер М.
Меьер Г.
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH
Текст визуальный непосредственный
Journal of Thrombosis and Haemostasis
John Wiley & Sons, Inc.
Vol.17, Issue10 P. 1772-1778
2019
Статья
anticoagulant agent apixaban low molecular weight heparin rivaroxaban apixaban blood clotting factor 10a inhibitor pyrazole derivative pyridone derivative rivaroxaban ambulatory care anticoagulant therapy Article cancer chemotherapy cancer patient cancer regression clinical outcome disease burden drug dose regimen drug efficacy drug use evidence based medicine human morbidity mortality patient preference patient selection practice guideline primary prevention priority journal randomized controlled trial (topic) thrombosis prevention treatment duration treatment response venous thromboembolism blood complication neoplasm oral drug administration risk factor treatment outcome venous thromboembolism Administration, Oral Evidence-Based Medicine Factor Xa Inhibitors Humans Neoplasms Pyrazoles Pyridones Randomized Controlled Trials as Topic Risk Factors Rivaroxaban Treatment Outcome Venous Thromboembolism
[краткое описание не найдено]